Primaquine Phosphate Tablets

Primaquine phosphate tablets are an established antimalarial medicine used primarily for radical cure of Plasmodium vivax and, where clinically appropriate, Plasmodium ovale infections by targeting dormant liver stages. Their use is governed by diagnosis, local resistance patterns, treatment guidelines, patient age, pregnancy status, and glucose-6-phosphate dehydrogenase (G6PD) status. Because primaquine can cause clinically significant hemolysis in people with G6PD deficiency, safe deployment depends on appropriate testing, prescribing, dispensing, and follow-up.

The landscape is being shaped by a stronger emphasis on radical cure, differentiated treatment protocols, and pharmacovigilance. Health systems increasingly link antimalarial selection to species identification, relapse risk, transmission objectives, and national guidelines rather than relying on undifferentiated fever treatment. G6PD testing remains a central operational requirement, while shortages, procurement procedures, product registration, storage conditions, and last-mile distribution can influence practical access. National malaria programs also continue to balance primaquine use with alternative therapies and evolving evidence on shorter or simplified regimens.

Artificial intelligence can support this field through image-assisted malaria diagnosis, clinical decision support, medicine-demand planning, pharmacovigilance signal detection, and adherence monitoring. These applications may help prioritize confirmatory testing, identify patients at risk of treatment interruption, and improve allocation of limited laboratory and public-health resources. However, AI does not replace G6PD testing, clinician judgment, validated diagnostics, or regulatory oversight. Performance can vary across populations and care settings, so implementation requires representative training data, transparent validation, privacy safeguards, and human review.

North America is primarily relevant to imported malaria, travel medicine, specialist care, and public-health surveillance. Latin America continues to require targeted approaches for P. vivax, especially in remote and forested areas where diagnosis, follow-up, and medicine access can be difficult. Europe likewise focuses largely on imported cases, migrant and traveler health, and preparedness in specialist services. The Middle East combines imported-case management with varied surveillance needs across countries. Africa remains central to malaria-control operations, although primaquine deployment must be aligned with local transmission patterns, diagnostic capacity, and G6PD-testing access. Asia-Pacific includes diverse endemic settings, including areas where P. vivax relapse prevention is a major concern and health systems range from highly developed to resource constrained.

ASEAN members face cross-border transmission, mobile populations, and differing malaria-control capacities, making coordination and surveillance important. BRICS countries span major endemic and non-endemic settings, with priorities ranging from elimination and case management to domestic manufacturing and supply resilience. The European Union supports harmonized evidence, cross-border health coordination, and imported-case management while national treatment decisions remain important. G7 countries contribute through research, surveillance, regulatory science, and financing, with use concentrated in travel medicine and specialist care in several members. GCC countries are particularly relevant to imported malaria surveillance and migrant-health services. NATO members have an additional interest in force health protection, deployment protocols, and reliable access to validated antimalarial treatment.

Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States mainly address imported malaria through travel clinics, hospitals, specialist services, and surveillance systems. Brazil, India, China, Indonesia-linked ASEAN supply networks, Mexico, and Russia combine varying degrees of endemic, border, imported, or elimination-focused activity, requiring country-specific protocols. South Korea emphasizes imported-case management and surveillance while retaining preparedness for regional risks. Across these countries, practical deployment depends on regulatory status, procurement channels, diagnostic confirmation, access to G6PD testing, clinician familiarity, and follow-up systems. National guidance should distinguish treatment of acute infection from prevention of relapse and should account for local parasite epidemiology and resistance evidence.

Industry and health-system leaders should align product strategy with national malaria guidelines, validated diagnostic pathways, and clear G6PD-testing workflows. Strengthening supply continuity requires qualified suppliers, quality-assured procurement, demand planning, appropriate packaging, and distribution designs suited to remote settings. Organizations should invest in prescriber and pharmacist education, patient counseling on adherence and hemolysis symptoms, and mechanisms for treatment follow-up. Digital and AI tools should be introduced only after clinical validation and should augment rather than replace professional decisions. Leaders should also monitor adverse events, treatment completion, resistance signals, and equity of access, using these findings to refine programs without compromising safety.

This executive summary uses a structured, qualitative review framework focused on verified public-health, clinical, regulatory, and epidemiological evidence relevant to primaquine phosphate tablets. The assessment considers the medicine’s therapeutic role, safety requirements, malaria species and relapse biology, diagnostic practice, procurement conditions, regional program context, and digital-health opportunities. Geographic comparisons are framed through established malaria-control priorities and health-system characteristics rather than commercial estimates. Interpretation should be updated as national guidelines, resistance evidence, G6PD-testing practices, product registrations, and surveillance findings change.

Primaquine phosphate tablets remain an important tool for preventing relapse in appropriate patients with susceptible P. vivax and P. ovale infections. Their value is inseparable from safe patient selection, G6PD assessment, accurate diagnosis, adherence support, and reliable supply. Regional and national needs differ substantially, so leaders should prioritize guideline alignment, quality assurance, surveillance, and locally appropriate delivery models. Artificial intelligence may strengthen these systems, but only when deployed with clinical safeguards, validated data, and accountable oversight.